GlassScriptPhysician profile
David Coffman
NPI 1578851739
$13,399.64
in general payments reported to CMS, 2019-2025
27 companies · $2,855 in 2025
The $2,855 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,233 · 2022: $2,634 · 2023: $3,009 · 2024: $2,668 · 2025: $2,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,531.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,775.05 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,207.68 | 2021-2025 | Trintellix |
| Abbvie INC. | $1,085.60 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,061.69 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,032.45 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $956.59 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $914.61 | 2021-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $827.35 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $825.07 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $810.22 | 2021-2025 | Fanapt, Hetlioz |
| Corium, LLC | $723.04 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $491.66 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $402.89 | 2022-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $233.69 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $208.68 | 2021-2024 | Adzenys Xr-Odt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $180.40 | 2021-2025 | Aplenzin |
| Eisai INC. | $168.65 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $148.58 | 2021 | |
| Merck Sharp & Dohme LLC | $68.09 | 2022-2023 | Belsomra |
| Almatica Pharma LLC | $61.48 | 2022 | |
| Tris Pharma INC | $60.65 | 2021-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $44.15 | 2024 | Secuado, Xelstrym |
| Collegium Pharmaceutical, INC. | $34.13 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $28.10 | 2021-2024 | |
| Sage Therapeutics, LLC | $20.41 | 2025 | Zurzuvae |
| Brainsway USA INC | $15.10 | 2025 | Deep Tms System |
| Adlon Therapeutics L.P. | $13.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Coffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.